IDWeek 2023
Boston, Massachusetts 11 October 2023 - 15 October 2023
Nirmatrelvir-ritonavir benefits persist against COVID
Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options.
Nirmatrelvir-ritonavir benefits persist against COVID
07 Nov 2023
One BPG dose may be enough to treat syphilis, regardless of HIV status
Three doses of benzathine penicillin G (BPG) are not necessarily better than a single dose in the treatment of early syphilis in individuals with or without HIV infection, as shown in a study.
One BPG dose may be enough to treat syphilis, regardless of HIV status
26 Oct 2023
Pooled EAGLE subgroup analyses boost gepotidacin potential for uUTI in females
In a pooled analyses of data from the EAGLE*-2 and EAGLE-3 studies, the investigational, first-in-class, oral, triazaacenaphthylene bactericidal antibiotic gepotidacin showed consistent therapeutic efficacy across key patient subgroups and had an acceptable safety profile in female adults and adolescents with uncomplicated urinary tract infections (uUTI) compared with nitrofurantoin.
